LFCR Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc. (LFCR) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.5% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.
Sector
Healthcare
Industry
Biotechnology